Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PRISM

- PMLiVE

Ipsen announces launch of new UK headquarters in London life sciences community

The Paddington site will serve as one of the company’s three global hubs

- PMLiVE

UCB’s Bimzelx recommended by CHMP to treat hidradenitis suppurativa in adults

The inflammatory skin disease affects an estimated 1% of the population in most studied countries

- PMLiVE

UCB reveals positive phase 3 results for Bimzelx in moderate-to-severe plaque psoriasis

Affecting 90% of psoriasis patients, the chronic autoimmune disease causes red, itchy, scaly patches

- PMLiVE

UCB presents positive long-term results for bimekizumab in hidradenitis suppurativa

The drug was associated with sustained improvements in the signs and symptoms of the inflammatory skin disease

- PMLiVE

MHRA approves UCB’s Rystiggo to treat generalised myasthenia gravis

The autoimmune disease has a global prevalence of 100 to 350 cases per every one million people

- PMLiVE

UCB presents positive phase 3 results for bimekizumab in hidradenitis suppurativa

The skin disease affects an estimated 1% of the population in most studied countries

- PMLiVE

ABPI publishes manifesto for government to accelerate UK life sciences industry

The trade association has called on political parties to commit to three broad goals and requirements

- PMLiVE

MHRA approves UCB’s Zilbrysq as generalised myasthenia gravis add-on therapy

The autoimmune disease has a global prevalence of 100 to 350 cases per every one million people

EU flag

EC approves UCB’s Rystiggo to treat generalised myasthenia gravis

The autoimmune disease has a global prevalence of 100 to 350 cases per every one million people

EU flag

EC approves UCB’s Zilbrysq as generalised myasthenia gravis add-on therapy

The autoimmune disease has a global prevalence of 100 to 350 cases per every one million people

- PMLiVE

UK’s Autumn Budget details measures to boost life sciences sector

The new budget will aim to advance research and manufacturing in the UK

- PMLiVE

ABPI report shows improvement in UK industry clinical trial performance

The data showed a 15% increase in annual recruitment to UK industry clinical trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links